Lyell Immunopharma (LYEL) Total Non-Current Liabilities (2020 - 2026)

Lyell Immunopharma's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $76.4 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 15.2% year-over-year to $76.4 million; the TTM figure through Mar 2026 stood at $76.4 million (down 15.2% YoY), while the FY2025 annual figure was $91.3 million, down 12.84% from the prior year.
• Total Non-Current Liabilities came in at $76.4 million for Q1 2026 at Lyell Immunopharma, down from $91.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $186.4 million in Q1 2022 to a low of $76.2 million in Q3 2025.
• A 5-year average of $102.4 million and a median of $91.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities plunged 50.31% in 2023 and rose 14.62% in 2024, its largest moves.
• Lyell Immunopharma's Total Non-Current Liabilities stood at $100.2 million in 2022, then fell by 8.77% to $91.4 million in 2023, then advanced by 14.62% to $104.8 million in 2024, then declined by 12.84% to $91.3 million in 2025, then dropped by 16.31% to $76.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $76.4 million, $91.3 million, and $76.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison